Ann: Quarterly Report and Appendix 4C, page-2

Reading through the quarterly I can not see anything that negative. Everything is on target with well placed timelines.
Management have delivered on what they have been promising from day one, and also a great appointment of Carol Parish
to help with EMA and FDA approval. 34 million to take us through ph3 , what’s not to like?
Capital 51 said after ph2 results that they would expect IXC to be trading at around the $2.00 mark, so at the current price
i think this is a bargain IMO. Problem is that some investors think waiting a year or two is too long and expect an overnight
buy out.
IMHO we will look back at the current share price in a year or two and be saying what a bargain price it is.